Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer (ZAK-0)
Phase 0 Study Aiming at Identifying Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
調査の概要
詳細な説明
研究の種類
段階
- 初期フェーズ 1
連絡先と場所
研究場所
-
-
-
Bordeaux、フランス、33076
- Institut Bergonie
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Written informed consent signed prior any study-related procedures.
- Histological diagnosis of colon cancer.
- Performance status ECOG 0, 1, or 2.
- Physical status score ASA 1 or 2.
- Patient without metastasis.
- No previous anti-cancer treatment for colon cancer.
- Age ≥ 18.
- Preoperative imaging: thorax-abdominal-pelvis CT scan within 2 months.
- Colonoscopy and biopsies to determine ZAK-0 expression level.
- Scheduled beginning of the treatment 7 days before surgical procedure.
Adequate end organ function as defined by:
11.1. total bilirubin < 1.5 x ULN,1 11.2. SGOT and SGPT < 2.5 x ULN, 11.3. creatinine < 1.5 x ULN, 11.4. Serum amylase and lipase ≤ 1.5 x ULN, 11.5. Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before initiation of study drug. Women of child-bearing potential must agree to use adequate contraception, according to investigator's instructions.
Effective contraception must be in place :
- During the treatment with nilotinib
- Until 2 weeks after the end of treatment.
- Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication): 13.1. Potassium ≥ LLN, 13.2. Magnesium ≥ LLN, 13.3. Phosphorus, ≥ LLN, 13.4. Total calcium (corrected for serum albumin) ≥ LLN.
- Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).
Exclusion Criteria:
- Rectal tumors (up to 15 cm from the anus)
- Any metastasis.
- Performance status ECOG ≥ 3.
- Physical status score ASA ≥ 3.
Impaired cardiac function including any one of the following:
5.1. LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by locally read echocardiogram. 5.2. Inability to determine the QT interval on ECG. 5.3. Complete left bundle branch block. 5.4. Use of a ventricular-paced pacemaker. 5.5. Congenital long QT syndrome or a known family history of long QT syndrome. 5.6. History of or presence of clinically significant ventricular or atrial tachyarrhythmias. 5.7. Clinically significant resting bradycardia (< 50 beats per minute). 5.8. QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient rescreened for QTc. 5.9. History of clinically documented myocardial infarction. 5.10. History of unstable angina (during the last 12 months). 5.11. Other clinically significant heart disease (e.g. congestive heart failure or uncontrolled hypertension).
- Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
- History of significant congenital or acquired bleeding disorder unrelated to cancer.
- Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery.
- History of non-compliance to medical regimens or inability to grant consent.
- Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon).
- Patients actively receiving therapy with strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- Patients actively receiving therapy with strong CYP3A4 inducers (e.g., dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John's Wort) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).
- History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.
- Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease.
- Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) female of childbearing potential unwilling to use contraceptive precautions throughout the trial and until two weeks after the end of treatment (post-menopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential). Contra-indication to nilotinib administration.
- Previous or current malignancies other than colon cancer within the last 5 years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin.
- Emergency surgeries, including occlusion.
- Previous enrolment in the present study.
- Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Nilotinib
A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status.
Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days.
The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours).
When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
|
Each patient will receive nilotinib 800 mg/day every day for 7 days.
Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food.
The entire capsule should be swallowed with water.
No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach
時間枠:Day 0
|
Day 0
|
ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach
時間枠:Day 7
|
Day 7
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Efficacy of the 7day nilotinib treatment based on histological response as measured with tumour regression grade
時間枠:Day 7
|
Day 7
|
Efficacy of the 7day nilotinib treatment based on histological response as measured with the proportion of tumour necrosis
時間枠:Day 7
|
Day 7
|
Efficacy of the 7day nilotinib treatment based on histological response as measured with the type of tumour necrosis
時間枠:Day 7
|
Day 7
|
Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v4.0 as assessed by CTCAE v4.0
時間枠:through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
Postoperative complications as assessed by Dindo and Clavien classification
時間枠:through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
Maximum Plasma Concentration [Cmax] of nilotinib .
時間枠:Day 7, day 8
|
Day 7, day 8
|
Half-life of nilotinib
時間枠:Day 7
|
Day 7
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
結腸がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ